New drugs in prostate cancer

The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Sangjun, Choi, Se Young, You, Dalsan, Kim, Choung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916061/
https://www.ncbi.nlm.nih.gov/pubmed/27358841
http://dx.doi.org/10.1016/j.prnil.2016.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916061/
https://www.ncbi.nlm.nih.gov/pubmed/27358841
http://dx.doi.org/10.1016/j.prnil.2016.05.001

Ejemplares similares